The rumor I heard two weeks ago was that it will be a few months before we hear anything from the FDA on approving Biogen's application for approval of aducanumab, but I don't know exactly what that means. Is that when they will begin their work, or is that when we should expect a conclusion?
In any event, we have just learned that they will at least begin their work very soon -- November 6. This will include, among other things, public hearings. This is what I learned from this article.
Aducanumab is not a cure for Alzheimer's disease, but, if it lives up to expectations, it is a major breakthrough that can give a measure of relief to many families and to the healthcare and elder care systems.
No comments:
Post a Comment